Healthy Male Individuals
Conditions
Brief summary
The purpose of this study is: To assess the pharmacokinetic profile and safety of ranolazine PR in healthy Korean and Caucasian volunteers after oral administration of Ranolazine at the doses of 375, 500, 750mg after single and repeated oral administrations.
Detailed description
Ranolazine is an antianginal drug that exerts its effects by inhibition of the late sodium current in cardiac cells. This action reduces intracellular sodium accumulation and consequently decreases intracellular calcium overload which is expected to reduce myocardial stiffness, oxygen consumption and ATP utilization and improve blood flow to the microvasculature.These effects of ranolazine do not depend upon reductions in heart rate or blood pressure or vasodilation. Ranolazine PR, approved for treatment of chronic angina in 56 countries and currently marketed in 21 countries including the US shows clinical efficacy and tolerability in the proposed therapeutic dose range from 375 mg to 750mg. Factors that may affect ranolazine pharmacokinetics including demographics, drug-drug interactions, disease state, CYP2D6 metabolizer genotype status and impaired renal or hepatic functions have been studied. The relationship between ranolazine plasma concentration and clinical effects has been also well-established. This PK study has been designed as a bridging study for Ranolazine PR registration in Korea.
Interventions
DRUGRanolazine
Sponsors
A.Menarini Asia-Pacific Holdings Pte Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
19 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adult Korean or Caucasian males, 19 - 45 years of age * Korean subjects: first generation of Korean subject born in Korea, both parents and the four grandparents must be of Korean origin. Proof of Korean ethnicity will be documented by medical interview and appropriate materials (e.g. Korean passport, Korean resident card) will be retained in the subject's folder * Caucasian subjects: first generation of Caucasian subject, both parents and the four grandparents of European descent. Documentation of ethnicity will be by medical interview and by appropriate materials (e.g. passport, birth certificate(if not available, a signed affirmation by the subjects)) will be retained in the subject's folder 2. Subjects weighing ≥ 50 kg with BMI between 18 and 27 kg/m2 (inclusive) at screening visit 3. Subjects with no clinically significant abnormal findings as determined by physical examination, ECG, medical history, or clinical laboratory test results 4. Subjects who agreed to voluntarily participate in this study and comply with all the study requirements by signing informed consent form after being informed of the nature of this study and understanding all aspects of this study
Exclusion criteria
1. History of clinically significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder 2. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug 3. Relevant chronic or acute infections 4. History of relevant allergy/hypersensitivity (including allergy to the trial medication or its excipients) 5. Administration of any investigational products within 3 months from the first dose of the study drug (ranolazine PR) 6. History of participating other BE study or clinical trial within 3 months from the first dose of the study drug(ranolazine PR) 7. Any of the following vital sign abnormalities * Systolic blood pressure: \<90 mmHg or \>140 mmHg * Diastolic blood pressure: \<50 mmHg or \> 90 mmHg * Pulse rate: \<50 bpm or \>90 bpm 8. Any of the following ECG abnormalities * PR \> 210 msec * QRS complex \> 120 msec * QTcF \> 430 msec 9. Any finding in the physical examination deviating from normal and judged clinically significant by the investigator 10. Any laboratory value outside of the reference range that the investigator considers to be of clinical significance 11. Subjects who have donated blood or received blood transfusion within 90 days of participating in this study 12. Subjects who are positive for Hepatitis B, Hepatitis C, VDRL and HIV 13. Subjects who showed positive result in alcohol and drug abuse tests 14. Subjects who have smoked over 10 cigarettes until 90 days prior to the study initiation or who is not able to stop smoking throughout the hospitalization period 15. Subjects who took prescribed medications within 14 days or over-the-counter (OTC) medications within 7 days prior to the first dose of the study drug (ranolazine PR) or who have to take these medications during the study period 16. Subject who judged not eligible for study participation by investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic assessment | Up to 5 days | Area under the plasma concentration versus time curve (AUC) |
| Pharmacokinetic Assessment | Up to 5 days | Plasma concentration (maximum,through, average) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events assessed using MedDRA | 5 days | Assessment based on reported symptoms, physical examination, vital signs, adverse events, ECGs, laboratory test results |
Countries
South Korea
Contacts
Primary ContactIn-Jin Jang, MD
Outcome results
None listed